Cancer newco Achilles debuts with L14.2M

Cancer company Achilles Therapeutics Ltd. (London, U.K.) raised L14.2 million ($18.3 million) in a venture round led by Syncona. The CRT Pioneer Fund of Cancer Research Technology and the UCL Technology Fund also participated.

Achilles intends to develop next-generation personalized vaccines and adoptive T cell therapies for metastatic cancer by targeting truncal tumor neoantigens. The company is based on research at University College London, Cancer Research UK (CRUK) and the Francis Crick Institute. ...